A Look at Eye Drops for Presbyopia: Aceclidine
Presbyopia, the difficulty in seeing close objects that typically appears around age 45, often leads us to reading glasses. But what if a simple eye drop could make a difference? A new category of treatments, eye drops for presbyopia, has emerged, and aceclidine is one of the most studied molecules in this innovative approach.
How Does It Work, Simply?
Imagine your eye as a camera. The pupil acts as the diaphragm, controlling light and depth of field. The aceclidine eye drop replicates this optical phenomenon, called "pinhole effect", in a controlled manner. It specifically targets the muscle that controls the pupil (the iris sphincter) to slightly reduce its size. This increases your depth of field, which improves near and intermediate vision, while leaving your distance vision unchanged.
What Results Can You Expect? 🎯
Clinical studies in the United States have shown that this treatment can be very helpful. It has been demonstrated that the eye drop improves near vision within about 30 minutes, an effect that can last up to 10 hours. This means that it can allow you to read messages on your phone or look at a menu in a restaurant without having to take out your reading glasses for a large part of the day. It is a temporary and practical solution to give you more freedom, without permanently "curing" presbyopia.
Limitations and Potential Side Effects
Effets courants
Les études ont montré que les effets indésirables les plus fréquents sont mild and transient. Ils peuvent inclure une légère irritation (20 %), de légers maux de tête (13 %), et une baisse de la vision dans des conditions de faible luminosité (16 %).
Risques de classe
Un risque de décollement de la rétine a été soulevé pour d'autres collyres moins sélectifs. L'acéclidine, grâce à son action ciblée et son impact minimal sur le muscle ciliaire, semble théoriquement Reducing this potential risk</
Availability and Reimbursement in France: The Current Market Reality
To date, this treatment is authorised only in the United States (under the name Vizz). It is therefore not yet available on the French or European market.
Consequently, it is currently not reimbursed by the National Health Insurance (Assurance Maladie) in France, as it has not yet been assessed by the Haute Autorité de Santé (HAS).
A Future Perspective
Aceclidine is a promising option for managing presbyopia. Although the product is not yet available in France, FDA approval and encouraging clinical data have opened up a new approach. As with any new treatment, discuss the most suitable option with your ophthalmologist.
References
Mechanism of Action and Pinhole Effect: Aceclidine - Wikipedia
Clinical Trial Data (CLARITY program): Aceclidine: the Latest Data from the CLARITY Clinical Trials
FDA Approval Information: FDA Approves Aceclidine (VIZZ) for Presbyopia in Adults - HCPLive
Side Effects and Safety Profile: New Eye Drop Approved for Presbyopia - Review of Optometry
Risk of Retinal Detachment with Miotics: Pilocarpine Drops for Presbyopia May Increase the Risk of Retinal Detachment - AAO
Regulatory Process in France (ANSM): Authorization for Market Entry for Medicines - ANSM
Reimbursement Process in France (HAS): Understanding the Evaluation of Medicines - Haute Autorité de Santé
Your ophthalmologist answers your questions during the consultation. For a sudden symptom or sudden loss of vision, seek advice promptly: see the eye emergencies page.